Soliris (Eculizumab) for PNH

Overview
Soliris is approved by the U.S. Food and Drug Administration (FDA) to treat people with paroxysmal nocturnal hemoglobinuria (PNH). Soliris is prescribed for individuals with PNH to reduce hemolysis (destruction of red blood cells), which helps improve symptoms like anemia and reduce the risk of complications related to blood clotting. Soliris is also known by its drug name, eculizumab.

Soliris is a complement inhibitor, meaning it works by blocking a part of the immune system known as the complement pathway. This prevents the complement system from mistakenly attacking red blood cells in individuals with PNH, thereby reducing hemolysis and its associated symptoms.

How do I take it?
Prescribing information states that Soliris is administered as an intravenous (IV) infusion. People receiving Soliris for PNH will follow a specific dosing schedule as outlined by their health care provider. It should be administered exactly as prescribed.

Side effects
Common side effects of Soliris in treating PNH include headache, nasopharyngitis (inflammation of the nasal passages and throat), back pain, and nausea.

Rare but serious side effects may include serious and life-threatening meningococcal infections, infusion-related reactions (such as nausea, dizziness, or rash), and increased susceptibility to other infections. 

For more information about this treatment, visit:

Label: Soliris — Eculizumab Injection, Solution, Concentrate — DailyMed